SCHEMBL16208365

SCHEMBL16208365

O=C(CSc1nc2cccnc2[nH]1)Nc1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.56
▸ TP53 P04637 1/20 0.56
▸ MPO P05164 1/20 0.56
▸ CCNK O75909 1/20 0.54
▸ CDK12 Q9NYV4 1/20 0.54
▸ ALDH1A1 P00352 3/20 0.54
▸ ENPP1 P22413 1/20 0.53
▸ POLB P06746 4/20 0.53
▸ LMNA P02545 2/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ RAB9A P51151 2/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ KLF5 Q13887 1/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ HPGD P15428 1/20 0.53
▸ RECQL P46063 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16208409 0.89 TSHR (0.59) MAPTTP53MPOALDH1A1POLB
SCHEMBL16208440 0.88 MPO (0.71) MAPTMPOALDH1A1POLBLMNA
SCHEMBL12487210 0.83 MPO (0.78) MAPTTP53MPOCCNKCDK12
SCHEMBL17624905 0.82 MAPT (0.74) MAPTTP53MPOALDH1A1POLB
SCHEMBL16208435 0.81 MPO (0.73) MAPTTP53MPOALDH1A1POLB
SCHEMBL20305142 0.81 ENPP1 (0.74) ALDH1A1ENPP1LMNATDP1SMN1; SMN2
SCHEMBL17531772 0.81 ENPP1 (0.68) MAPTMPOCCNKCDK12ALDH1A1
SCHEMBL16208348 0.80 MAPT (0.59) MAPTTP53MPOCCNKCDK12
SCHEMBL17538636 0.79 MAPT (0.75) MAPTMPOALDH1A1ENPP1POLB
SCHEMBL16208375 0.76 MAPT (0.57) MAPTTP53MPOCCNKCDK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9643933-B2 Compounds useful as antibiotic tolerance inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2017-05-09 — — US disclosed
US-9643933-B2 Compounds useful as antibiotic tolerance inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2017-05-09 — — US disclosed
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2016-02-25 — — US disclosed
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2016-02-25 — — US disclosed
WO-2014176258-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2014-10-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS CFTR, SLC11A2, MRPS18A MAPT 4629/4885TP53 2990/4885MPO 981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback